Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Letrozole & Breast Cancer / Mammacarcinoma (HR+) (ER+)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Letrozole is FDA and EMA approved for the treatment of Breast Cancer / Mammacarcinoma (HR+), specifically for postmenopausal women in both adjuvant and advanced/metastatic settings (1, 2)

(1) Cohen et al. 2011 Oncologist 16(12): 1762-70
(2) Bhatnagar 2007 Breast Cancer Res Treat 105(Suppl 1): 3-5

…

Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval
Cohen et al. 2011 Oncologist 16(12): 1762-70
Review
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase III trial
Smith et al. 2020a
The early days of letrozole
Bhatnagar 2007 Breast Cancer Res Treat 105(Suppl 1): 3-5
Review
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase III trial
Mamounas et al. 2019 Lancet Oncol 20(1): 88-99

7/1/2026